Compumedics (ASX:CMP) granted U.S. FDA for Neuroimaging technology
- Compumedics (CMP) has received clearance from the U.S. Food and Drug Administration (FDA) for its neuroimaging technology
- The clearance allows for routine clinical use of the MEG devices, mainly for epilepsy and pre-surgical brain function mapping
- Sites using the technology can now routinely bill private and public insurance plans for the examination
Add to My Watchlist
What is My Watchlist?
